Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Concord Medical Services ( (CCM) ) just unveiled an announcement.
On December 2, 2025, Concord Medical Services announced its 2025 annual general meeting of shareholders scheduled for December 29, 2025, in Beijing. The meeting will not involve any proposals for shareholder approval but will serve as a platform for shareholders to discuss company affairs with management. This event underscores Concord Medical’s commitment to transparency and stakeholder engagement, potentially impacting its operational strategies and market perception.
The most recent analyst rating on (CCM) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on Concord Medical Services stock, see the CCM Stock Forecast page.
Spark’s Take on CCM Stock
According to Spark, TipRanks’ AI Analyst, CCM is a Underperform.
Concord Medical Services is facing significant financial challenges, with negative earnings and cash flows, and a heavily leveraged balance sheet. Technical indicators also suggest a bearish outlook, and valuation metrics are poor, reflecting the company’s ongoing struggles.
To see Spark’s full report on CCM stock, click here.
More about Concord Medical Services
Concord Medical Services Holdings Limited is a healthcare provider in China specializing in oncology services, including cancer diagnosis, treatment, education, and prevention. The company operates a network of self-owned and partnered cancer hospitals and clinics, equipped with advanced technology such as proton therapy systems, aiming to enhance the quality and accessibility of cancer care.
Average Trading Volume: 17,562
Technical Sentiment Signal: Strong Sell
Current Market Cap: $16.8M
Learn more about CCM stock on TipRanks’ Stock Analysis page.